Skip to content

Repligen RGEN Granted (in shares)

Granted (in shares) at other companies

Charles River Laboratories logo
Charles River LaboratoriesCRL
$135.00
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
7K
Essential Utilities logo
Essential UtilitiesWTRG
$193.92K+24.4%
AeroVironment logo
AeroVironmentAVAV
0
Coeur Mining logo
Coeur MiningCDE
3.5M
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$502.97

Other financials

Income statement

See full
Revenue$194.3M+14.8%
Gross profit$108.3M+18.5%
Operating income$15.9M+142%
Net income$8.3M+42.9%
EPS (diluted)$0.15+50.0%

Balance sheet

See full
Cash & equivalents$582.7M-16.4%
Total debt$687.6M+346%
Total equity$2.1B+6.0%
Total assets$2.9B+2.8%

Cash flow

See full
Operating cash flow$28.3M+88.6%
CapEx$4.7M+32.2%
Free cash flow$23.6M+106%

Valuation

See full
Market cap$7.45B-7.1%
Enterprise value$7.55B+2.1%
P/E144.9×
P/S10.1×-0.1×

Profitability

See full
Gross margin49.5%+2.7pp
Operating margin1.5%-14.0pp
Net margin17.1%-3.7pp
FCF margin21.2%+6.1pp

Returns & leverage

See full
Return on equity2.5%+1.9pp
Debt / equity0.3×+0.2×
Current ratio9.2×+2.4×

Where this comes from

Reported directly by Repligen in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.

The official record: Repligen’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Repligen's granted (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Repligen's granted (in shares)?
Repligen (RGEN) reported granted (in shares) of 211.5K in Q1 2026.
What does granted (in shares) mean?
The total number of equity instruments, such as restricted stock units (RSUs) or performance stock units (PSUs), granted during the period that are distinct from traditional stock options. This metric captures the company's use of alternative equity-based vehicles to incentivize and retain talent. It is essential for assessing the total dilution impact of non-option equity compensation.